Two concurrent multi-center phase 2 studies have confirmed the utility of using unrelated double umbilical cord blood (dUCB) or HLA-haploidentical donor bone marrow grafts in reduced-intensity hematopoietic cell transplantation (HCT). The two trials, conducted by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), found 1-year overall and progression-free survival were 54% and 46%, respectively, after dUCB transplantation (n=50), and 62% and 48%, respectively, after haploidentical marrow transplantation (n=50). The authors note that because patients were not randomly assigned to one trial or the other, the outcomes cannot be compared directly. Rather, these two multi-center studies set the stage for BMT CTN 1101, a phase 3 randomized trial currently accruing participants, that will directly compare these transplant graft sources.
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Parallel Phase 2 Trials Confirm Utility of Both Haploidentical and Cord Blood HCT
Jul 2011